Bridging: Perioperatives Vorgehen bei dauerhafter oraler Antikoagulation oder Plättchenfunktionshemmung

Zusammenfassung

Orale Antikoagulanzien [Vitamin-K-Antagonisten, Dabigatran, Rivaroxaban, Apixaban] und Plättchenfunktionshemmer (PH) [ASS, Clopidogrel, Prasugrel, Ticagrelor] werden alleine oder kombiniert zur Prävention und Behandlung thromboembolischer Erkrankungen eingesetzt. Patienten mit Indikation zu einer dauerhaften Antikoagulation [Vorhofflimmern, mechanischer Herzklappenersatz, venöse Thromboembolie] oder PH-Therapie [zerebro- oder kardiovaskuläre Ereignisse] benötigen bei interventionellen oder chirurgischen Eingriffen eine vorübergehende Umstellung auf entsprechende Medikamente mit einer kurzen Wirkungsdauer. Die aktuellen Empfehlungen für das praktische Vorgehen drücken sich aufgrund einer begrenzten Datenlage in schwachen Empfehlungsgraden aus, sodass zur Planung einer überbrückenden gerinnungshemmenden Therapie [„Bridging“] bei jedem Patienten das Blutungs- und Thromboembolierisiko gegeneinander abgewogen werden müssen. Bei einem mittleren Thromboembolierisiko bestimmt das individuell zu ermittelnde Blutungsrisiko der geplanten Intervention die überbrückende Therapie: Ist das Blutungsrisiko durch die geplante Intervention gering, kann die orale Antikoagulation/PH-Therapie in den meisten Fällen unverändert weitergeführt oder in ihrer Intensität geringfügig reduziert werden. Ist bei mittlerem bis hohem Blutungsrisiko das Thromboserisiko gering, kann die gerinnungshemmende Therapie auch kurzfristig pausiert werden. Bei hohem Thromboembolie- und Blutungsrisiko wird die Umstellung der oralen Antikoagulation mit unfraktioniertem [eingeschränkte Nierenfunktion] oder fraktioniertem Heparin durchgeführt. Die PH-Therapie kann bei hohem Thromboembolie- und Blutungsrisiko mit kurzwirksamen GPIIb-IIIa Antagonisten [Eptifibatide; Tirofiban] überbrückt werden. Patienten, die auf die neuen oralen Antikoagulanzien [Dabigatran, Rivaroxaban, Apixaban] eingestellt sind, benötigen vor elektiven Interventionen in Abhängigkeit von der Halbwertszeit und der individuellen Nierenfunktion eine Behandlungspause und müssen vor OP nicht mit Heparinen überbrückt werden.

Abstract

Oral anticoagulants [Vitamin-K-Antagonists, Dabigatran, Rivaroxaban, Apixaban] or antiplatelet agents [Aspirin, Clopidogrel, Prasugrel, Ticagrelor] are effective in preventing thromboembolic diseases. In case of interventional of surgical procedures patients with indications for chronic anticoagulation [atrial fibrillation, valve prosthesis, venous thromboembolism] or use of antiplatelet agents [cerebrovascular events, cardiovascular events] will require interruption of antithrombotic/antiplatelet therapy with the need of replacement with a short-acting agent. Due to limited data available from randomized studies and meta-analyses the evidence level is low in the majority of recommendations. Therefore for each patient the bleeding and thrombosis risk depending on the individual patient constitution and the planned intervention must be weighted. In patients with an intermediate risk for thrombosis the bleeding risk of the scheduled intervention will influence the bridging recommendation: In patients with a low bleeding risk oral anticoagulation/antiplatelet therapy can be continued or reduced in intensity. In patients with an intermediate or high bleeding risk along with a low thrombosis risk a temporary interruption of the anticoagulation/antiplatelet therapy is feasible. In patients with a high thrombosis and bleeding risk anticoagulation should be bridged with unfractionated heparin [renal insufficiency] or low molecular weight heparin. In the latter risk situation, inhibition of platelet function can be achieved with short-lasting GPIIb-IIIa inhibitors [Eptifibatide, Tirofiban]. Prior to intervention patients treated with the new oral anticoagulants [Dabigatran; Rivaroxaban; Apixaban] are requested to temporary interrupt the anticoagulation depending on the individual drug half-life and their renal function. Bridging therapy with heparin prior to intervention is not necessary with the new oral anticoagulants.

Schlüsselwörter

Bridging - orale Antikoagulation - Plättchenfunktionshemmer - neue orale Antikoagulanzien

Keywords

bridging - oral anticoagulants - platelet function inhibition - new oral anticoagulants

• Literatur

• 1 Angiolillo DJ, Firstenberg MS, Price MJ et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. A randomized controlled trial. JAMA 2012; 307: 265-274
• 2 Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol 2013; 163: 160-167
• 3 Barequet IS, Sachs D, Priel A et al.  Phacoemulsification of cataract in patients receiving Coumadin therapy: ocular and hematologic risk assessment. Am J Ophthalmol 2007; 1445: 719-723
• 4 BRIDGE study investigators. Bridging anticoagulation. Is it needed when warfarin is interrupted around the time of a surgery or procedure – cardiology patient page. Circulation 2012; 125: e496-e498
• 5 Ceppa DP, Welsby IJ, Wang TY et al. Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection. Ann Thorac Surg 2011; 92: 1971-1976
• 6 Dimitrova G, Tulman DB, Bergese SD. Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR proceedings in intensive care and cardiovascular Anesthesia 2012; 4: 153-167
• 7 Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011; 117: 5044-5049
• 8 Douketis JD, Spyropoulos AC, Spencer FA et al. American College of Chest Surgeons. Perioperative management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [erratum appears in Chest 2012;141(4):1129]. Chest 2012; 141 (Suppl. 02) e326S-e350S
• 9 Hammerstingl C, Schmitz A, Fimmers R et al. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovascular therapeutics 2009; 27: 230-238
• 10 Halbritter KM, Wawer A, Beyer J et al. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective registry of 311 episodes. J Thromb Haemost 2005; 3: 2823-2825
• 11 Healey J, Eiklboom J, Douketis J et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin – results from the randomised evaluation of long-term anticoagulation therapy (RE-LY) randomised trial. Circulation 2012; 126: 343-348
• 12 Hillarp A, Baghaei F, Fagerberg Blixter I et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139
• 13 Lip GY, Huber K, Andreotti F et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28
• 14 Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb Res 2009; 1243: 292-299
• 15 Joist JH, George JN. Hemostatic abnormalities in liver and renal disease. In: Colman RW, Hirsh J, Marder VJ, et al eds. Hemostasis and thrombosis. Basic Principals and Clinical Practice. Philadelphia: Lippincott, Williams & Wilkins; 2004: 955-973
• 16 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511
• 17 Koscielny J, Beyer-Westendorf J, von Heymann C et al. Risk of bleeding and haemorrhagic complication with rivaroxaban-periprocedural management of haemostasis – Konsensus. Hamostaseologie 2012; 32 (04) 287-293
• 18 Koscielny J, Rutkauskaite E. Preinterventional change in the clotting medication. Viszeralmedizin (Gastrointestinal Medicine and Surgery) 2013; 29: 1-13
• 19 Korte W, Cattaneo M, Chassot PG et al. Perioperative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105 (05) 743-749
• 20 Kozek-Langenecker S, Afshari A, Albaladejo P et al. Management of severe perioperative bleeding. Guidelines from the European Society of Anaesthesiology EJA 2013; 30: 270-382
• 21 Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521
• 22 Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematology 2012; 529-535
• 23 Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 9: 1705-1712
• 24 Levy JH, Faraoni D, Spring JL et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466-1474
• 25 Patel M, Mahaffey K, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
• 26 Patel JP, Arya R. The current status of bridging anticoagulation. Br J Haematol 2013; DOI: 10.1111/bjh.12644.
• 27 Pfanner G, Koscielny J, Pernerstorfer T et al. Die präoperative Blutungsanamnese. Empfehlungen der Arbeitsgruppe perioperative Gerinnung (AGPG) der Österreichischen Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin (ÖGARI). Anaesthesist 2007; 56 (06) 604-611
• 28 Ramström G, Sindet-Pedersen S, Hall G et al. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. J Oral Maxillofac Surg 1993; 5111: 1211-1216
• 29 Robinson GA, Nylander A. Warfarin and cataract extraction. Br J Opthamol 1989; 73: 702-703
• 30 Samama MM, Contant G, Spiro TE et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387
• 31 Savonitto S, D'Urbano M, Caracciolo M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104: 285-291
• 32 Schulman S, Kearon C. on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost 2005; 3: 692-694
• 33 Schellong SM, Haas S. Perioperative Thromboseprophylaxe – Neue orale Antikoagulanzien und ihre Anwendung. Anästhesiol Intensivmed Notfallmed Schmerzther 2012; 47: 266-272
• 34 S3 - Leitlinie Polytrauma/Schwerverletzten-Behandlung. Deutsche Gesellschaft für Unfallchirurgie. AWMF (Arbeitskreis wissenschaftlicher medizinischer Fachgesellschaften); Register Nr. 012/019, 290. 1-445
• 35 Siegal D, Yudin J, Kaatz S et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639
• 36 Sørensen R, Hansen ML, Abildstrom SZ et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374 (9706) 1967-1974
• 37 Spyropoulos AC, Albaladejo P, Godier A et al. Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. J Thromb Haemost 2013; 11 (08) 1593-156
• 38 Spyropoulos A, Douketis JD, Gerotziafas G. on behalf of the subcommittee on control of anticoagulation of the SSC of the ISTH et al. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost 2012; 10: 692-694
• 39 The Society of Thoracic Surgeons Blood Conservation Guideline Task Force, The Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists. Clinical Practice Guideline. Ann Thorac Surg 2007; 83 (Suppl. 01) S27-S86
• 40 Thiele T, Sumnig A, Hron G et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost 2012; 10: 968-971
• 41 Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 4412: 1227-1246
• 42 van Ryn J, Tangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127
• 43 Vincentelli A, Susen S, le Turneau E et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349